165 related articles for article (PubMed ID: 21427386)
1. Influence of donor cytomegalovirus (CMV) status on severity of viral reactivation after allogeneic stem cell transplantation in CMV-seropositive recipients.
Pietersma FL; van Dorp S; Minnema MC; Kuball J; Meijer E; Schuurman R; van Baarle D
Clin Infect Dis; 2011 Apr; 52(7):e144-8. PubMed ID: 21427386
[TBL] [Abstract][Full Text] [Related]
2. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction.
Yakushiji K; Gondo H; Kamezaki K; Shigematsu K; Hayashi S; Kuroiwa M; Taniguchi S; Ohno Y; Takase K; Numata A; Aoki K; Kato K; Nagafuji K; Shimoda K; Okamura T; Kinukawa N; Kasuga N; Sata M; Harada M
Bone Marrow Transplant; 2002 Apr; 29(7):599-606. PubMed ID: 11979310
[TBL] [Abstract][Full Text] [Related]
4. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients.
Ugarte-Torres A; Hoegh-Petersen M; Liu Y; Zhou F; Williamson TS; Quinlan D; Sy S; Roa L; Khan F; Fonseca K; Russell JA; Storek J
Biol Blood Marrow Transplant; 2011 Apr; 17(4):574-85. PubMed ID: 20688181
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
[TBL] [Abstract][Full Text] [Related]
6. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
[TBL] [Abstract][Full Text] [Related]
7. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
Avetisyan G; Larsson K; Aschan J; Nilsson C; Hassan M; Ljungman P
Bone Marrow Transplant; 2006 Nov; 38(10):687-92. PubMed ID: 17001346
[TBL] [Abstract][Full Text] [Related]
8. High incidence of cytomegalovirus reactivation in adult recipients of an unrelated cord blood transplant.
Takami A; Mochizuki K; Asakura H; Yamazaki H; Okumura H; Nakao S
Haematologica; 2005 Sep; 90(9):1290-2. PubMed ID: 16154862
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for cytomegalovirus, hepatitis B and C virus reactivation after bone marrow transplantation.
Zekri AR; Mohamed WS; Samra MA; Sherif GM; El-Shehaby AM; El-Sayed MH
Transpl Immunol; 2004 Dec; 13(4):305-11. PubMed ID: 15589744
[TBL] [Abstract][Full Text] [Related]
10. Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.
Ganepola S; Gentilini C; Hilbers U; Lange T; Rieger K; Hofmann J; Maier M; Liebert UG; Niederwieser D; Engelmann E; Heilbronn R; Thiel E; Uharek L
Bone Marrow Transplant; 2007 Mar; 39(5):293-9. PubMed ID: 17262060
[TBL] [Abstract][Full Text] [Related]
11. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
[TBL] [Abstract][Full Text] [Related]
12. Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure.
Nakamura R; Battiwalla M; Solomon S; Follmann D; Chakrabarti S; Cortez K; Hensel N; Childs R; Barrett AJ
Biol Blood Marrow Transplant; 2004 Jan; 10(1):49-57. PubMed ID: 14752779
[TBL] [Abstract][Full Text] [Related]
13. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation.
Widmann T; Sester U; Gärtner BC; Schubert J; Pfreundschuh M; Köhler H; Sester M
PLoS One; 2008; 3(11):e3634. PubMed ID: 18982061
[TBL] [Abstract][Full Text] [Related]
14. Effect of cytomegalovirus (CMV) serostatus on the incidence and virological features of active CMV infection in allogeneic stem cell transplant recipients.
Solano C; Tormo N; de la Cámara R; Bartolo Nieto J; López J; Benet I; Muñoz-Cobo B; Costa E; Remigia MJ; Garcia-Noblejas A; Bravo D; Navarro D
Clin Infect Dis; 2011 Aug; 53(3):313-5; author reply 315-6. PubMed ID: 21765090
[No Abstract] [Full Text] [Related]
15. The Mexican schedule to conduct allogeneic stem cell transplantation is related to a low risk of cytomegalovirus reactivation and disease.
Ruiz-Argüelles GJ; Rangel JD; Ponce-de-León S; González-Déctor L; Reyes-Núñez V; Garcés-Eisele J
Am J Hematol; 2004 Apr; 75(4):200-4. PubMed ID: 15054809
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation.
Lin TS; Zahrieh D; Weller E; Alyea EP; Antin JH; Soiffer RJ
Transplantation; 2002 Jul; 74(1):49-54. PubMed ID: 12134098
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus antibody avidity in allogeneic bone marrow recipients: evidence for primary or secondary humoral responses depending on donor immune status.
Lutz E; Ward KN; Szydlo R; Goldman JM
J Med Virol; 1996 May; 49(1):61-5. PubMed ID: 8732861
[TBL] [Abstract][Full Text] [Related]
18. Response to antiviral therapy in haematopoietic stem cell transplant recipients with cytomegalovirus (CMV) reactivation according to the donor CMV serological status.
Servais S; Dumontier N; Biard L; Schnepf N; Resche-Rigon M; Peffault de Latour R; Scieux C; Robin M; Meunier M; Xhaard A; Sicre de Fontbrune F; Le Goff J; Socié G; Simon F; Mazeron MC
Clin Microbiol Infect; 2016 Mar; 22(3):289.e1-7. PubMed ID: 26627339
[TBL] [Abstract][Full Text] [Related]
19. Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.
Moins-Teisserenc H; Busson M; Scieux C; Bajzik V; Cayuela JM; Clave E; de Latour RP; Agbalika F; Ribaud P; Robin M; Rocha V; Gluckman E; Charron D; Socié G; Toubert A
J Infect Dis; 2008 Sep; 198(6):818-26. PubMed ID: 18666855
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients.
Kamar N; Mengelle C; Esposito L; Guitard J; Mehrenberger M; Lavayssière L; Ribes D; Cointault O; Durand D; Izopet J; Rostaing L
J Med Virol; 2008 Jun; 80(6):1012-7. PubMed ID: 18428146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
